Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Mu opioid receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Onchocerca volvulus | Mitochondrial inner membrane protein homolog | Mu opioid receptor | 398 aa | 334 aa | 23.1 % |
Echinococcus granulosus | allatostatin A receptor | Mu opioid receptor | 398 aa | 346 aa | 29.5 % |
Schistosoma mansoni | neuropeptide F-like receptor | Mu opioid receptor | 398 aa | 335 aa | 20.6 % |
Schistosoma japonicum | ko:K04134 cholinergic receptor, invertebrate, putative | Mu opioid receptor | 398 aa | 334 aa | 24.9 % |
Echinococcus multilocularis | allatostatin A receptor | Mu opioid receptor | 398 aa | 341 aa | 29.3 % |
Onchocerca volvulus | Mu opioid receptor | 398 aa | 333 aa | 26.4 % | |
Schistosoma japonicum | Rhodopsin, putative | Mu opioid receptor | 398 aa | 328 aa | 23.2 % |
Onchocerca volvulus | Mu opioid receptor | 398 aa | 376 aa | 26.3 % | |
Echinococcus multilocularis | thyrotropin releasing hormone receptor | Mu opioid receptor | 398 aa | 371 aa | 27.0 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Mu opioid receptor | 398 aa | 397 aa | 22.7 % |
Onchocerca volvulus | Mu opioid receptor | 398 aa | 356 aa | 23.9 % | |
Echinococcus granulosus | thyrotropin releasing hormone receptor | Mu opioid receptor | 398 aa | 370 aa | 27.3 % |
Onchocerca volvulus | Programmed cell death protein 5 homolog | Mu opioid receptor | 398 aa | 323 aa | 24.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | CAAX prenyl protease 2 | 0.0185 | 1 | 1 |
Plasmodium vivax | protease, putative | 0.0038 | 0.1149 | 0.5 |
Schistosoma mansoni | family U48 unassigned peptidase (U48 family) | 0.0185 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0185 | 1 | 1 |
Echinococcus multilocularis | ATP dependent DNA helicase PIF1 | 0.0084 | 0.3921 | 0.3921 |
Toxoplasma gondii | hypothetical protein | 0.0038 | 0.1149 | 0.5 |
Trypanosoma brucei | DNA repair and recombination helicase protein PIF7 | 0.0084 | 0.3921 | 0.3921 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0084 | 0.3921 | 0.3921 |
Entamoeba histolytica | hypothetical protein, conserved | 0.0084 | 0.3921 | 0.3921 |
Mycobacterium ulcerans | hypothetical protein | 0.0038 | 0.1149 | 1 |
Trypanosoma brucei | CAAX amino terminal protease, putative | 0.0185 | 1 | 1 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0084 | 0.3921 | 0.3921 |
Schistosoma mansoni | family U48 unassigned peptidase (U48 family) | 0.0185 | 1 | 1 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF6, putative | 0.0084 | 0.3921 | 0.3921 |
Entamoeba histolytica | CAAX prenyl protease family | 0.0185 | 1 | 1 |
Mycobacterium tuberculosis | Probable integral membrane protein | 0.0038 | 0.1149 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0185 | 1 | 1 |
Plasmodium falciparum | protease, putative | 0.0038 | 0.1149 | 0.5 |
Entamoeba histolytica | CAAX amino terminal protease family | 0.0038 | 0.1149 | 0.1149 |
Giardia lamblia | Rrm3p helicase | 0.0084 | 0.3921 | 0.3921 |
Toxoplasma gondii | CAAX amino terminal protease family protein | 0.0038 | 0.1149 | 0.5 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0084 | 0.3921 | 0.3921 |
Trypanosoma cruzi | CAAX prenyl protease 2, putative | 0.0185 | 1 | 1 |
Mycobacterium tuberculosis | Probable conserved integral membrane protein | 0.0038 | 0.1149 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0084 | 0.3921 | 0.3921 |
Treponema pallidum | hypothetical protein | 0.0038 | 0.1149 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0038 | 0.1149 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0038 | 0.1149 | 1 |
Leishmania major | CAAX prenyl protease 2, putative,peptidase with unknown catalytic mechanism (family U48) | 0.0185 | 1 | 1 |
Entamoeba histolytica | DNA repair and recombination protein, putative | 0.0084 | 0.3921 | 0.3921 |
Trypanosoma cruzi | peptidase with unknown catalytic mechanism (family U48) | 0.0185 | 1 | 1 |
Echinococcus granulosus | ATP dependent DNA helicase PIF1 | 0.0084 | 0.3921 | 0.3921 |
Entamoeba histolytica | CAAX amino terminal protease family | 0.0038 | 0.1149 | 0.1149 |
Mycobacterium ulcerans | hypothetical protein | 0.0038 | 0.1149 | 1 |
Echinococcus granulosus | CAAX prenyl protease 2 | 0.0185 | 1 | 1 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0084 | 0.3921 | 0.3921 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0084 | 0.3921 | 0.3921 |
Trypanosoma brucei | DNA repair and recombination helicase protein PIF6 | 0.0084 | 0.3921 | 0.3921 |
Mycobacterium ulcerans | integral membrane protein | 0.0038 | 0.1149 | 1 |
Chlamydia trachomatis | hypothetical protein | 0.0038 | 0.1149 | 0.5 |
Trichomonas vaginalis | Clan U, family U48, CaaX prenyl peptidase 2-like | 0.0185 | 1 | 1 |
Mycobacterium tuberculosis | Probable conserved integral membrane protein | 0.0038 | 0.1149 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | nM | Concentration that reduced the response by 50% by delta selective analogue was assessed in mouse vas deferens assay; NA is no activity at 10e-5 M | ChEMBL. | 2537426 |
IC50 (binding) | = 49 nM | Binding potency of compound in competition with [3H]-CTOP for Opioid receptor mu 1 tested in rat brain membrane | ChEMBL. | 2537426 |
IC50 (binding) | = 20000 nM | Binding potency of compound in competition with [3H]-DPDPE for Opioid receptor delta 1 tested in rat brain membrane | ChEMBL. | 2537426 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.